Henry Schein (NASDAQ:HSIC) Price Target Raised to $110.00

Henry Schein (NASDAQ:HSIC) had its price objective lifted by BTIG Research from $100.00 to $110.00 in a research note released on Wednesday, MarketBeat.com reports. The firm currently has a buy rating on the stock.

Several other research analysts also recently issued reports on HSIC. Wall Street Zen raised Henry Schein from a “hold” rating to a “buy” rating in a report on Monday, August 17th. Stifel Nicolaus set a $95.00 target price on Henry Schein in a research report on Wednesday, August 5th. Piper Sandler upped their price target on Henry Schein from $91.00 to $95.00 and gave the company an “overweight” rating in a research note on Wednesday, July 29th. Morgan Stanley reiterated an “underweight” rating and issued a $64.00 price target (up from $61.00) on shares of Henry Schein in a report on Friday, April 24th. Finally, Barrington Research set a $104.00 price objective on Henry Schein in a research report on Wednesday, August 5th. Eight investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $92.93.

Henry Schein Stock Up 0.0%

Shares of NASDAQ:HSIC opened at $88.50 on Wednesday. The company has a quick ratio of 0.73, a current ratio of 1.32 and a debt-to-equity ratio of 0.60. The firm has a market cap of $9.86 billion, a P/E ratio of 25.80, a P/E/G ratio of 1.69 and a beta of 0.80. Henry Schein has a 12 month low of $61.94 and a 12 month high of $92.18. The company’s 50-day moving average price is $85.74 and its two-hundred day moving average price is $79.52.

Henry Schein (NASDAQ:HSIC) last announced its earnings results on Tuesday, August 4th. The company reported $1.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.24 by $0.03. Henry Schein had a net margin of 2.96% and a return on equity of 15.97%. The company had revenue of $3.46 billion for the quarter, compared to analyst estimates of $3.37 billion. During the same period in the prior year, the business earned $1.10 earnings per share. Henry Schein’s quarterly revenue was up 6.7% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. As a group, research analysts forecast that Henry Schein will post 5.35 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Invesco Ltd. raised its holdings in Henry Schein by 4.1% in the third quarter. Invesco Ltd. now owns 4,731,698 shares of the company’s stock worth $314,043,000 after purchasing an additional 184,763 shares during the period. Southpoint Capital Advisors LP raised its stake in Henry Schein by 28.0% during the 1st quarter. Southpoint Capital Advisors LP now owns 3,200,000 shares of the company’s stock worth $235,840,000 after buying an additional 700,000 shares during the period. Dimensional Fund Advisors LP lifted its holdings in Henry Schein by 2.0% during the first quarter. Dimensional Fund Advisors LP now owns 2,873,004 shares of the company’s stock worth $211,734,000 after acquiring an additional 56,687 shares in the last quarter. Ameriprise Financial Inc. lifted its holdings in Henry Schein by 11.3% during the third quarter. Ameriprise Financial Inc. now owns 2,523,014 shares of the company’s stock worth $167,453,000 after acquiring an additional 256,156 shares in the last quarter. Finally, Bank of Montreal Can grew its stake in Henry Schein by 3,655.7% in the fourth quarter. Bank of Montreal Can now owns 2,144,773 shares of the company’s stock valued at $162,102,000 after acquiring an additional 2,087,666 shares during the period. Institutional investors own 96.62% of the company’s stock.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.